AFT hits US approval target, triggers cash

AFT hits US approval target, triggers cash
Managing director Hartley Atkinson said Maxigesic was an effective alternative for the US$700 million of IV paracetamol sold each year. (Photo: supplied).
Dan Brunskill
The United States medical regulator has accepted an application for AFT Pharmaceuticals’ patented pain relief medicine, which if approved would open up a more than US$300 million market.The US Food and Drug Administration has formally received the application for Maxigesic IV, an intravenous form of AFT’s painkiller, which was filed in August this year.Filing with the FDA triggers milestone payments worth US$3.6m under a licensing deal with US partner Hikma Pharmaceuticals. This will be recognised in the first half of the current fi...

More Markets

NZ sharemarket dips as big stocks weigh despite KMD gains
Markets

NZ sharemarket dips as big stocks weigh despite KMD gains

The NZ sharemarket closed down, although KMD Brands lifted on a positive result.

Tom Raynel 19 Nov 2025
Investor days to test gentailer plans for new build and firming
Markets

Investor days to test gentailer plans for new build and firming

Investors want answers on build delays, capital plans and Huntly’s future.

Ian Llewellyn 19 Nov 2025
Argosy delivers strong first-half results
Economy

Argosy delivers strong first-half results

Earnings and net tangible asset value per share up. 

Andy Macdonald 19 Nov 2025
Asset Plus' first-half profit lower as Munroe Lane in focus
Economy

Asset Plus' first-half profit lower as Munroe Lane in focus

First-half net tangible assets per share down on the year. 

Andy Macdonald 19 Nov 2025